scholarly journals Metformin: new perspectives in chemoprevention and therapy of cancer

2018 ◽  
Vol 17 (3) ◽  
pp. 12-19
Author(s):  
A. V. Shestakov ◽  
T. V. Saprina ◽  
I. A. Anufrak ◽  
O. E. Gonchikova ◽  
A. L. Chernysheva

According to modern data, metformin is a unique drug, which can act not only as sugar-reducing medicine, but also as an antiproliferative element. More and more new researches about metformin effects in oncologic patients appear during last decades. A lot of researchers suppose that metformin is a new promising medicine for chemopreventive and neoadjuvant cancer therapy. This literature review covers current researches of metformin in context of it»s possible antiproliferative effects.

1999 ◽  
Vol 92 (Supplement) ◽  
pp. S31
Author(s):  
Main G. Flores ◽  
Gary Dunkerley ◽  
Barry Lindenberg

2020 ◽  
Vol 1 ◽  
pp. 100021
Author(s):  
Madison Grinnell ◽  
Kerri E. Rieger ◽  
Tamiko R. Katsumoto ◽  
Bernice Y. Kwong ◽  
Lisa C. Zaba

2021 ◽  
Vol 4 (3) ◽  
pp. 13584-13594
Author(s):  
Aline Rodrigues de Freitas ◽  
Beatriz de Roig Gatto ◽  
Caroline Brandão Chiovatto ◽  
Isabelly Menezes Argentino ◽  
Rodrigo Alessandro Riemma Vela ◽  
...  

Author(s):  
ZAKARIYA AL-MASHHADANI ◽  
RUA A. NASER ◽  
MUNAF H. ZALZALA

Rapid development has achieved in treating tumor to stop malignant cell growth and metastasis in the past decade. Numerous researches have emerged to increase potency and efficacy with novel methods for drug delivery. The main objective of this literature review was to illustrate the impact of current new targeting methods to other previous delivering systems to select the most appropriate method in cancer therapy. This review first gave a brief summary of cancer structure and highlighted the main roles of targeting systems. Different types of delivering systems have been addressed in this literature review with focusing on the latest carrier derived from malarial protein. The remarkable advantages and main limitations of the later have been also discussed. PubMed and Science Direct were the main search engines that have been used as information sources to prepare this review. Articles related to cancer targeting system, active and passive processes, current nanoparticles, antibody carriers, and current novel cancer carriers were used as sources in this review. Important points from many references published in the last decade (2008-2018) were selected and included. Several targeting methods were introduced to enhance the efficacy and tolerability of the toxic drug by active and passive processes, but there is still no conclusive carrier without certain drawbacks. A combination of targeting methods probably shows the most appropriate choice for increasing selectivity and safety of anticancer drugs via reducing the concentration of carriers used.


2021 ◽  
Vol 22 (16) ◽  
pp. 8439
Author(s):  
Monika Zajkowska ◽  
Barbara Mroczko

Colorectal cancer (CRC) is one of the most common types of malignancy, with an annual incidence of about 10% of the total number of new cases. Despite well-developed screening tests, mortality from this type of cancer remains unchanged. Therefore, it is important to search for more accurate markers that are useful in the detection of colorectal cancer (especially in its early stages), and treatment. Angiopoietin-like proteins (ANGPTLs) are a family of eight proteins with a diversity of applications, including pro- and anti-angiogenic properties. Consequently, we performed an extensive search of the literature, pertaining to our investigation, via the MEDLINE/PubMed database. Based on the available literature, we summarize that some of those proteins are characterized by increased or decreased concentrations during the course of CRC. We can also assume that some ANGPTLs can inhibit the development of CRC, while others induce its progress. Moreover, some factors are dependent on the stage or histological type of the tumor, the presence of hypoxia, or metastases. Most importantly, some ANGPTLs can be useful in anti-cancer therapy. Therefore, further studies on ANGPTLs as potential markers of CRC should be continued.


2008 ◽  
Vol 88 (2) ◽  
pp. 67-79 ◽  
Author(s):  
Colin D. White ◽  
Alan J. Stewart ◽  
Zhi-Liang Lu ◽  
Robert P. Millar ◽  
Kevin Morgan

2014 ◽  
Vol 4 (1) ◽  
Author(s):  
Daniela Zanolin ◽  
Christine Widmer ◽  
Eva-Maria Panfil

Mucositis is one of the most common side effects of chemotherapy and radiotherapy. In order to develop an evidence-based clinical practice guideline for the management of tumor therapy-induced-oral mucositis, it was necessary to capture the patients’ perspective. Therefore the aim of this critical literature review was to explore the experience of patients with therapy-induced-oral mucositis. Searches were carried out using a systematic search strategy in CINAHL and Medline. Qualitative studies investigating the view of cancer patients receiving chemotherapy and/or radiotherapy and suffering from oral mucositis were included. Study selection and quality assessment were performed by two independent reviewers. Only two qualitative studies (n=28 patients) met the inclusion criteria. Oral mucositis caused by cancer therapy is associated with serious complications concerning pain, eating, swallowing, speaking, sadness, lack of energy, and distress. Mucositis was described as the worst side effect of cancer therapy. Providing patient-centered care requires understanding the experience and the needs of patients and their families. Mucositis is associated with complex physical, psychological and social consequences. Unfortunately, both studies were performed in different cultural backgrounds and health care systems, so the results cannot simply be transferred to German-speaking countries. Further research is needed to gain a deeper understanding of living with mucositis.


Sign in / Sign up

Export Citation Format

Share Document